Merck KGaA (ETR:MRK)
Germany · Delayed Price · Currency is EUR | Market Cap | 54.59B -11.6% |
| Revenue (ttm) | 21.27B +1.5% |
| Net Income | 2.96B +9.6% |
| EPS | 6.80 +9.8% |
| Shares Out | 434.78M |
| PE Ratio | 18.47 |
| Forward PE | 14.79 |
| Dividend | 2.20 (1.75%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 238,077 |
| Average Volume | 304,982 |
| Open | 124.70 |
| Previous Close | 125.85 |
| Day's Range | 124.10 - 127.20 |
| 52-Week Range | 100.70 - 151.70 |
| Beta | 0.73 |
| RSI | 50.59 |
| Earnings Date | Mar 5, 2026 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables, devices, instruments, software, and services for research, production, and testing; process solutions consisting of filtration devices, chromatography... [Read more]
Full Company ProfileFinancial Performance
In 2024, Merck KGaA's revenue was 21.16 billion, an increase of 0.78% compared to the previous year's 20.99 billion. Earnings were 2.78 billion, a decrease of -1.66%.
Financial StatementsNews
EQS-AFR: Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQS Preliminary announcement financial reports: Merck KGaA / Preliminary announcement on the disclosure of financial statements Merck KGaA: Preliminary announcement of the publication of quarterly rep...
EQS-AFR: Merck KGaA: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Merck KGaA / Preliminary announcement on the disclosure of financial statements Merck KGaA: Preliminary announcement of the publication of financial rep...
EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Merck KGaA Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 21.01.2...
Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
2026-01-15. The following slide deck was published by Merck KGaA in conjunction with this event.
Merck KGaA (MKKGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
Not intended for media outside the U.S. or Canada EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced today that the U.S. Food and Drug Administrat...
MilliporeSigma: Curiosity Cub Completes 2025 Tour, Inspiring Future Innovators Through AI
NORTHAMPTON, MA / ACCESS Newswire / January 8, 2026 / Each year, the Curiosity Cube, a mobile science lab from MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Ge...
Merck KGaA: Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER study In MANEUVER, pimicotinib significantly improved objective response rate at week 25 ...
Why Immunome, A Top 3% Stock, Just Rocketed On Its Rivalry With Merck KGaA
Top-notch biotech stock Immunome rocketed Monday after the company's treatment for desmoid tumors appeared to top an approved drug.
Thin-Film Electrode Market worth $0.97 billion by 2030 at 11.3%, says MarketsandMarkets™
Delray Beach, FL, Dec. 15, 2025 (GLOBE NEWSWIRE) -- In terms of value, the Thin-Film Electrode Market is projected to projected to reach USD 0.97 billion by 2030, at a CAGR of 11.3% from USD 0.57 bill...
Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case
The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.
Dr. Rasha Kelej of Merck Foundation Meets Nigeria First Lady at the Merck Foundation Africa Asia Luminary 2025
Business Wire India Merck Foundation, the philanthropic arm of Merck KGaA Germany, recently conducted the 12th Edition, “Merck Foundation Africa...
Merck Foundation Observes the ‘Day for Elimination of Violence Against Women 2025’ Through Their More Than a Mother Campaign and Educating Linda Program
Business Wire India Merck Foundation, the philanthropic arm of Merck KGaA Germany, together with The First Ladies of Africa and...
Equinix Hosts Merck KGaA's HPC at its Data Center in Germany
EQIX hosts Merck KGaA's new liquid-cooled high-performance computer in Germany, blending private and public cloud to boost scalable, efficient scientific computing.
Valo Health Partners with Merck KGaA in $3B AI Drug Discovery Deal
Valo Health Partners with Merck KGaA in $3B AI Drug Discovery Deal
Merck KGaA inks $3B deal to discover Parkinson’s drugs using AI
EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Merck KGaA Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 20....
Merck KGaA to draw on Valo's drug discovery AI in potential $3 billion deal
Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused on Parkinson's and related diseases that is potentially worth over $3 billio...
Valo Health Announces Collaboration with Merck KGaA, Darmstadt, Germany to Discover and Develop Novel Treatments for Parkinson's Disease and Related Disorders
LEXINGTON, Mass.--(BUSINESS WIRE)--Valo Health announces collaboration with Merck KGaA, Darmstadt, Germany to discover and develop novel treatments for Parkinson's and related disorders.
Merck KGaA (MKKGY) Q3 2025 Earnings Call Transcript
Merck KGaA (OTCPK:MKKGY) Q3 2025 Earnings Call November 13, 2025 8:00 AM ESTCompany ParticipantsFlorian Schraeder - Head of Investor RelationsBelén Garijo...
Merck KGaA 2025 Q3 - Results - Earnings Call Presentation
Merck KGaA (MKGAF) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amidst Market Challenges
Merck KGaA (MKGAF) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amidst Market Challenges
Q3 2025 Merck KGaA Earnings Call Transcript
Q3 2025 Merck KGaA Earnings Call Transcript
Merck KGaA Non-GAAP EPS of €2.32, revenue of €5.32B; updates FY outlook
Merck KGaA Q3 Profit Rises On Organic Growth Across All Sectors
BRUSSELS (dpa-AFX) - Merck KGaA (MKKGY) on Thursday reported higher profit for the third quarter, supported by organic growth across all three business sectors - Life Science, Healthcare, and Elec...